| Literature DB >> 26682008 |
K Yanar1, U Çakatay1, S Aydın1, A Verim2, P Atukeren1, N E Özkan3, K Karatoprak4, T Cebe4, S Turan3, E Ozkök5, G Korkmaz3, C Cacına3, O Küçükhüseyin3, İ Yaylım3.
Abstract
Nitric oxide synthase (eNOS/NOS3) is responsible for the endothelial synthesis of nitric oxide (NO(•)). G894T polymorphism leads to the amino acid substitution from Glu298Asp that causes lower NOS3 activity and basal NO(•) production in NOS3 894T (298Asp) allele carriers compared with the GG homozygotes. NO(•) acts as an antioxidant protecting against Fenton's reaction which generates highly reactive hydroxyl radicals. Allelic variation of NOS3 may influence an individual's risk of laryngeal cancer (LC). In the current study we have examined the possible relationship between NOS3 G894T genotypes and various systemic oxidative damage markers such as protein carbonyl, advanced oxidation protein products, Cu, Zn-superoxide dismutase, thiol group fractions, and lipid hydroperoxides in LC patients. Genotyping was carried out by PCR-RFLP. In LC patients with TT genotype, Cu, Zn-superoxide dismutase activities and nonprotein thiol levels were significantly higher than the controls. In patients with GT and GG genotype, high levels of lipid hydroperoxides showed statistical significance when compared to controls. Our results indicate a potential relationship among G894T polymorphism of NOS3, and impaired redox homeostasis. Further studies are required to determine the role of NOS3 gene polymorphism and impaired plasma redox homeostasis.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26682008 PMCID: PMC4670686 DOI: 10.1155/2016/4985063
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Restriction band pattern of G894T polymorphism in exon 7 of the NOS3 gene. Agarose gel electrophoresis of PCR products after endonuclease restriction with enzyme BannII. Lane 1, GG homozygote (163 bp and 85 bp); lane 2, GT heterozygote (248 bp, 163 bp, and 85 bp); and lane 3, TT homozygote (248 bp). M represents 50 bp ladder.
Characteristics of patients with laryngeal carcinoma.
| Parameters | Larynx cancer patients | |
|---|---|---|
|
| % | |
| Reflux | ||
| Yes | 26 | 44.8 |
| No | 32 | 55.2 |
| Family history of any kind of cancer | ||
| Yes | 17 | 30.9 |
| No | 38 | 69.1 |
| Tumor location | ||
| Glottic | 38 | 69.1 |
| Supraglottic | 17 | 30.9 |
| Tumor grade | ||
| T1 | 8 | 14.1 |
| T2 | 10 | 17.5 |
| T3 | 30 | 52.6 |
| T4 | 9 | 15.8 |
| Lymph node | ||
| N0 | 36 | 62.1 |
| N1 | 20 | 34.5 |
| N2 | 2 | 3.4 |
| Metastasis | ||
| Yes | 1 | 1.8 |
| No | 54 | 98.2 |
| Differentiation | ||
| Poor | 8 | 14 |
| Medium | 38 | 66.7 |
| Well | 11 | 19.3 |
| Tumor recurrence | ||
| Yes | 8 | 13.8 |
| No | 50 | 86.2 |
Genotypes and allele frequencies of NOS3 Glu298Asp in primary larynx cancer patients and their controls. Hardy-Weinberg equilibrium analysis showed the genotype distribution for the NOS3 gene (G894T) in larynx cancer patients in accordance with Hardy-Weinberg equilibrium.
| Patients | Controls | |
|---|---|---|
|
|
| |
| Genotype | ||
| GG | 18 (31) | 31 (21.1) |
| GT | 29 (50) | 81 (55.1) |
| TT | 11 (19) | 35 (23.8) |
|
| ||
|
| ||
| Alleles | ||
| G | 65 (56.03) | 143 (48.64) |
| T | 51 (43.97) | 151 (51.36) |
|
| ||
Variations in the levels of plasma oxidative stress parameters of larynx cancer patients and their controls.
| Patients | Controls |
| |
|---|---|---|---|
| PCO (nmol/mg pr) | 1.19 ± 0.08 | 0.86 ± 0.08 | 0.008 |
| AOPP ( | 56.04 ± 5.61 | 41.04 ± 5.22 | 0.037 |
| Total thiol (nmol/mg pr) | 15.54 ± 1.19 | 16.23 ± 1.55 | 0.843 |
| Nonprotein thiol (nmol/mg pr) | 3.35 ± 0.30 | 3.46 ± 0.19 | 0.703 |
| Protein thiol (nmol/mg pr) | 12.17 ± 1.19 | 12.86 ± 1.51 | 0.860 |
| LHP ( | 3.71 ± 0.42 | 1.20 ± 0.12 | 0.000 |
| Cu, Zn-SOD (U/mg pr) | 7.27 ± 0.31 | 5.99 ± 0.34 | 0.004 |
p < 0.05; p < 0.01.
Mean ± SD values of oxidative stress parameters according to NOS3 genotypes in larynx cancer patients and controls.
| GG | GT | TT | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients | Controls |
| Patients | Controls |
| Patients | Controls |
| |
| PCO | 1.3 ± 0.2 | 1.0 ± 0.3 | 0.517 | 1.2 ± 0.1 | 0.9 ± 0.1 | 0.125 | 1.1 ± 0.1 | 0.7 ± 0.1 | 0.088 |
| AOPP | 54.1 ± 9.4 | 43.4 ± 6.7 | 0.833 | 52.7 ± 6.4 | 34.6 ± 7.8 | 0.029 | 66.4 ± 18.9 | 48.3 ± 10.1 | 0.562 |
| Total thiol | 16.8 ± 3.2 | 21.9 ± 3.0 | 0.315 | 15.5 ± 1.6 | 13.9 ± 2.0 | 0.371 | 14.1 ± 1.2 | 16.4 ± 3 | 0.731 |
| Nonprotein thiol | 3.4 ± 0.9 | 4.0 ± 0.5 | 0.524 | 2.9 ± 0.3 | 3.4 ± 0.3 | 0.363 | 4.4 ± 0.3 | 3.3 ± 0.3 | 0.037 |
| Protein thiol | 13.0 ± 3.3 | 17.7 ± 2.6 | 0.315 | 12.8 ± 1.6 | 10.7 ± 2.1 | 0.285 | 9.7 ± 1.3 | 13.1 ± 2.9 | 0.628 |
| LHP | 4.2 ± 0.8 | 1.4 ± 0.3 | 0.006 | 4.0 ± 0.6 | 1.3 ± 0.2 | 0.001 | 2.4 ± 1.0 | 1.1 ± 0.2 | 1.22 |
| Cu, Zn-SOD | 6.9 ± 0.4 | 5.9 ± 0.6 | 0.279 | 7.2 ± 1.8 | 6.4 ± 0.6 | <0.05 | 7.9 ± 0.8 | 5.5 ± 0.5 | 0.036 |
p < 0.05; p < 0.01; p < 0.001.